[{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"BRAZIL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Eszopiclone","moa":"GABA-A receptor; anion channel","graph1":"Sleep","graph2":"Phase IV","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"11","companyTruncated":"University of Sao Paulo \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Murdoch Childrens Research Institute","sponsor":"Monash Health | Royal Children's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Murdoch Childrens Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Spray","sponsorNew":"Murdoch Childrens Research Institute \/ Monash Health | Royal Children's Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Murdoch Childrens Research Institute \/ Monash Health | Royal Children's Hospital"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Sao Paulo \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VA Loma Linda Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Sleep","graph2":"Phase IV","graph3":"VA Loma Linda Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Pill","sponsorNew":"VA Loma Linda Health Care System \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"VA Loma Linda Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Columbia University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Merck & Co"},{"orgOrder":0,"company":"Kurume University","sponsor":"Eisai Inc | Mebix","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase IV","graph3":"Kurume University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kurume University \/ Eisai Inc | Mebix","highestDevelopmentStatusID":"11","companyTruncated":"Kurume University \/ Eisai Inc | Mebix"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Eisai | Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of California, San Francisco \/ Eisai | Stanford University","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Eisai | Stanford University"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase IV","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"JZP258","moa":"Oxybate receptors (GABA-B)","graph1":"Sleep","graph2":"Phase IV","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JZP258","moa":"Oxybate receptors (GABA-B)","graph1":"Sleep","graph2":"Phase IV","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JZP258","moa":"Oxybate receptors (GABA-B)","graph1":"Sleep","graph2":"Phase IV","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Dominik Ettlin","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Sleep","graph2":"Phase IV","graph3":"Dominik Ettlin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dominik Ettlin \/ Merz Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Dominik Ettlin \/ Merz Pharma"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Pennsylvania \/ Axsome Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Charles A. Czeisler","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Charles A. Czeisler","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Charles A. Czeisler \/ Axsome Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Charles A. Czeisler \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Chloral Hydrate","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanovia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmanovia \/ Undisclosed"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Lindus Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Chloral Hydrate","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanovia \/ Lindus Health","highestDevelopmentStatusID":"11","companyTruncated":"Pharmanovia \/ Lindus Health"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Max Zeller Soehne","sponsor":"University of Basel","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Valerian-Hop Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Max Zeller Soehne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Zeller Soehne \/ University of Basel","highestDevelopmentStatusID":"11","companyTruncated":"Max Zeller Soehne \/ University of Basel"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
